Brief: Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
12/11/2025 12:37
Nov 12 (Reuters) - Alkermes Plc ALKS.O: ALKERMES ANNOUNCES POSITIVE TOPLINE RESULTS FROM VIBRANCE-2 PHASE 2 STUDY OF ONCE-DAILY ALIXOREXTON IN PATIENTS WITH NARCOLEPSY TYPE 2 ALKERMES PLC - ALIXOREXTON MEETS DUAL PRIMARY ENDPOINTS IN PHASE 2 STUDY ALKERMES PLC - ALIXOREXTON GENERALLY WELL TOLERATED AT ALL DOSES ALKERMES PLC: PLANS TO INITIATE ALIXOREXTON NARCOLEPSY GLOBAL PHASE 3 PROGRAM IN Q1 OF 2026 Source text: ID:nPreCL3d2a Further company coverage: ALKS.O ((reuters.briefs@thomsonreuters.com;))